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Abstract
Background—The decline in asbestos use in the United States may impact mesothelioma 
incidence.
Objective—This report provides national and state-specific estimates of mesothelioma incidence 
in the United States using cancer surveillance data for the entire US population.
Methods—Data from the National Program for Cancer Registries and the Surveillance, 
Epidemiology, and End Results program were used to calculate incidence rates and annual percent 
change.
Results—During 2003–2008, an average of 1.05 mesothelioma cases per 100 000 persons were 
diagnosed annually in the United States; the number of cases diagnosed each year remained level, 
whereas rates decreased among men and were stable among women.
Conclusion—US population-based cancer registry data can be used to determine the burden of 
mesothelioma and track its decline. Even 30 years after peak asbestos use in the United States, 
3200 mesothelioma cases are diagnosed annually, showing that the US population is still at risk.
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Introduction
Exposure to asbestos may cause non-malignant diseases, such as asbestosis, chronic airway 
obstruction, pleural plaques, diffuse and localized pleural thickening, and rounded 
atelectasis;1–3 cancers of the lung, larynx, and ovary;4 and malignant mesothelioma.4,5 
Mesothelioma can originate in the lining of the lung or chest cavity (pleura), in the lining of 
the abdomen (peritoneum), or other sites, such as the pericardium and tunica vaginalis.6 
Mesothelioma is caused principally by exposure to asbestos.4,5 All forms of asbestos, 
including the serpentine form (chrysotile) and the amphibole forms (i.e. crocidolite, amosite, 
anthophyllite, treomolite, and actinolite), as well as some other fibrous minerals (e.g. 
erionite) cause mesothelioma.4 Even a low-level or relatively brief exposure to asbestos is 
linked with a low, non-zero, risk of developing mesothelioma.7,8 The latent period between 
first exposure to asbestos and mesothelioma is generally 30 years or more.9
Use of asbestos began in the United States in the late 1800s, peaked in the early 1970s with 
more than 800 000 metric tons produced or imported in 1973, and has since declined, 
although 1100 metric tons were still imported in 2011.10,11 Partially on the basis of these 
usage patterns and data from the National Cancer Institute’s (NCI) Surveillance, 
Epidemiology, and End Results (SEER) registries, which covers 9% (SEER nine registries) 
to 26% (SEER 17 registries) of the US population,12 some investigators predicted that 
mesothelioma incidence in the United States would peak around the year 2000 with 2400–
2500 cases being diagnosed per year.13–15 The first nationally representative mesothelioma 
incidence rates for 1999–2002 were estimated by using data from 40 states and the District 
of Columbia (DC) (covering 88% of the US population) that were reported to the Centers for 
Disease Control and Prevention’s (CDC) National Program for Cancer Registries (NPCR) 
and SEER.16 These data showed that predictive models restricted to SEER data might yield 
conservative estimates of the number of mesothelioma cases.16 Cancer surveillance data 
from NPCR and SEER now provide 100% coverage of the US population for 2003–2008 
and are used here to update national and state-specific mesothelioma incidence rates and 
counts.
Methods
Information was obtained about cases of malignant mesothelioma diagnosed during 2003–
2008, as reported to an NPCR or SEER population-based cancer registry, and submitted to 
CDC or NCI by November 2010.17 In each US state and the DC, local and regional cancer 
data are reported to NPCR or SEER central cancer registries about all new diagnoses of 
cancer from patient records at such medical facilities as hospitals, physicians’ offices, 
therapeutic radiation facilities, free-standing surgical centers, and pathology laboratories. 
The central cancer registries collate these data and use state vital records, and the National 
Death Index to collect information about any cancer deaths that were not reported as cases. 
These data are submitted to CDC or NCI and combined into one dataset. Combined, the 
NPCR and SEER cancer registries cover all of the US population and provide the only 
source of information on population-based cancer incidence for the nation. Cancer registries 
demonstrated that cancer incidence data were of high quality by meeting six US Cancer 
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Statistics (USCS) publication criteria.17 All registries met these criteria for each year during 
2003–2008, covering 100% of the US population.
Mesothelioma cases were identified by using the International Classification of Diseases for 
Oncology third edition (ICD-O-3).18 Cases were defined by anatomic sites (pleura [C38.4], 
peritoneum [C48], and other mesothelioma [all other ICD-O-3 codes]). Most (98%) pleural 
and peritoneal mesothelioma cases were diagnosed in medical facilities and 2% were found 
by death certificate or autopsy; 82% of ‘other’ mesothelioma cases were diagnosed in 
medical facilities and 8% were found by death certificate or autopsy.
Population estimates used in the SEER*Stat software (www.seer.cancer.gov/seerstat) were a 
modified version of the annual time series of July 1 county population estimates by age, sex, 
and race/ethnicity produced by the US Census Bureau.19 Modifications incorporated 
bridged, single-race estimates that were derived from multiple-race categories in the 2000 
Census20 and accounted for known issues in certain counties.19 The modified county-level 
population estimates, summed to the state and national levels, were used as denominators in 
rate calculations.19
Average annual incidence rates per 100 000 persons were age-adjusted to the 2000 US 
standard population by the direct method.21 Corresponding 95% confidence intervals (CIs) 
were calculated as modified gamma intervals.22 All rate calculations were performed by 
using SEER*Stat. Mesothelioma incidence rates were examined by sex, age, race/ethnicity, 
and state. Incidence rates were calculated for all races and ethnicities combined and for each 
of five major racial/ethnic populations (i.e. white, black, American Indian or Alaska Native, 
Asian or Pacific Islander, and Hispanic). Information about race and Hispanic ethnicity were 
collected separately. An algorithm was applied to Hispanic ethnicity data to reduce 
misclassification of Hispanic persons as being of unknown ethnicity.23
Trends in age-standardized cancer incidence rates and counts were analyzed by using 
joinpoint regression, which characterizes the trends as annual percent change.24 The t-test 
was used to test whether the annual percent change was statistically different from zero 
(P<0.05). The Pearson correlation was used to evaluate associations between male and 
female mesothelioma incidence rates and between pleural and peritoneal incidence rates 
within states. These analyses were weighted by the inverse variance of the male and female 
combined mesothelioma incidence rate and restricted to states where at least 16 cases were 
diagnosed for each sex or subsite to allow for reliable rates (i.e. 42 states for correlation by 
sex; 28 states for correlation by subsite). All statistical tests were two-sided.
Maps depicting the geographic distribution of the number of mesothelioma cases and the 
age-adjusted mesothelioma incidence rates used the twenty-fifth, fiftieth, seventy-fifth, and 
ninetieth percentiles as cutpoints.
Results
During 2003–2008, 19 011 cases of mesothelioma were diagnosed in the United States, 
approximately 3200 per year (Table 1). The average annual age-adjusted incidence rate 
during this period was 1.05 (95% CI: 1.03–1.06) cases per 100 000 population. Rates were 
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higher among men (rate=1.93) than among women (rate=0.41). The highest rates were 
observed among white men (rate=2.06).
Rates were similar among men and women younger than 45 years, but then diverged as rates 
began to increase more rapidly with age among men (Table 1). Rates were highest among 
men aged 75 years or older (Table 1).
The anatomic site where mesothelioma was diagnosed differed by sex and age. Among men, 
85% of cases were diagnosed in the pleura and 7% in the peritoneum, compared with 73% 
diagnosed in the pleura and 18% in the peritoneum among women (differences significant 
P<0.05) (Table 1). Most (66%) cases classified as ‘other’ mesothelioma were diagnosed in 
the lung (ICD-O-3 codes 34.0–34.9).
By age, among those younger than 45 years at diagnosis, 44% of cases were diagnosed in 
the pleura, compared with 77% among those aged 45–64 years and 85% among those aged 
65 years or older (differences significant P<0.05) (Table 2). The correlation between 
incidence rates of pleural and peritoneal mesothelioma within states was 0.70 (P<0.0001) 
(Fig. 1A).
Incidence rates among states ranged from 0.58 to 1.65 per 100 000 persons (Fig. 2A). The 
average rate among states in the upper tenth percentile (Alaska, Maine, New Jersey, West 
Virginia, and Washington) was 1.51 (Fig. 2A). Rates among women tended to be higher in 
states where rates among men were also high (Pearson correlation r=0.78; P<0.0001) (Fig. 
1B).
Incidence rates decreased by 2.6% per year from 2003 to 2008 among men and were stable 
among women (Fig. 3). The number of cases diagnosed each year remained the same from 
2003 to 2008 with about 2500 cases among men and 700 cases among women diagnosed 
each year (Fig. 3).
Discussion
This report updates national and state-specific mesothelioma incidence in the United States 
on the basis of 40 states and DC (88% of the US population) for 1999–200216 with data 
from all 50 states and DC, providing 100% coverage of the US population for 2003–2008. 
National estimates of mesothelioma incidence extrapolated from SEER data underestimated 
the true number of cases.13–15 For some cancers, including pleural neoplasms, rates 
calculated in the SEER nine areas may not be representative of US rates.25,26 US 
mesothelioma rates appear to be higher than those from the SEER nine registries, but similar 
to those from the SEER 17 registries, which include states with high rates of mesothelioma, 
such as New Jersey and Louisiana.12 Several ecological studies have shown linear 
associations between historical asbestos use and mesothelioma incidence and mortality 
rates.27–29 Based on incidence data during 1995–2000 and asbestos use 25 years earlier, 
countries with high historical asbestos use tended to have the highest mesothelioma 
incidence rates such as Australia (3.5 cases per 100 000 people), Great Britain (3.3), and the 
Netherlands (3.0); US rates (1.4) were about the same as countries with similar asbestos use 
Henley et al. Page 4
Int J Occup Environ Health. Author manuscript; available in PMC 2015 April 22.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
(2.6 kg per capita per year).29 Patterns of asbestos use suggest that the mesothelioma disease 
burden is shifting toward countries with recent use of asbestos.28,30
The temporal trends in our data agree with trends based on SEER nine data, which show that 
mesothelioma incidence rates among men increased until the early 1990s, remained level for 
several years, and then began to decline about 2005, while rates among women increased 
slightly during 1975–1986 and had little change during 1986–2008.12 Based on data from 83 
countries covering 29% of the world population, worldwide mesothelioma mortality 
increased 5.4% per year from 1994 through 2008.30 A study of the relation between asbestos 
use and mesothelioma mortality among men found increasing mortality from 1996 through 
2005 in five countries (Japan, Croatia, Hungary, Argentina, and Brazil) and stable trends in 
26 countries including Australia and the United Kingdom.28
Age-adjusted incidence rates can be influenced by several factors, including the size or 
overall age of the population.21 If the size or overall age of the US population or both 
increased over time, the rate may go down, even if the number of cases stayed the same or 
increased during that time. Our study shows that during 2003–2008, the number of 
mesothelioma cases and incidence rate were stable among women, and among men the 
number of cases remained the same although the rate of mesothelioma incidence declined. A 
decline in the mesothelioma rate does not necessarily imply that there were fewer 
mesothelioma cases or fewer people exposed to asbestos.
In the United States, men tend to have the highest mesothelioma incidence rate, which may 
reflect differences in occupational exposures.31 Historically people, primarily men, were 
exposed to asbestos from working in asbestos-related industries, such as asbestos mining 
and manufacturing, ship building, and construction.32 Currently, about 1.3 million workers 
in the United States and 125 million workers around the world are exposed to asbestos.33 In 
an effort to protect US workers from occupational exposure to asbestos, standards were 
recommended by the National Institute for Occupational Safety and Health in 1972 (revised 
in 1976)34 and issued by the Occupational Safety and Health Administration in 1972 
(revised in 1996).35 Today, most workers are exposed to asbestos primarily through the 
demolition, remediation, and maintenance of buildings, including homes and schools, 
containing asbestos.32,36
In addition, differences in industry may explain geographic variability in mesothelioma 
incidence. States with high mesothelioma rates tended to have had shipyard industries, such 
as Washington and Maine, or asbestos manufacturing industries, such as New Jersey.37 In 
West Virginia, mesothelioma incidence was highest among counties with large industries 
(e.g. coal mining, power plants, and chemical plants); workers in these industries are 
considered at high risk of asbestos exposure and have a high risk of death from 
mesothelioma.32,38 Given that most contemporary exposure in the United States may come 
from being around buildings built with asbestos-laden materials,32 these geographic patterns 
may shift. A recent study in Australia estimated that home renovation was the largest source 
of non-occupational asbestos exposure for both men and women; of mesothelioma cases 
diagnosed during 2005–2008, 8% among men and 36% among women were due to 
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exposures during home renovation.36 Geographic patterns also may shift following 
widespread community exposure to asbestos, as occurred in Libby, Montana.39,40
As observed previously,16 US mesothelioma incidence rates were highest among older men 
and women who were probably exposed to asbestos before IARC classified it as a human 
carcinogen,41 and before efforts were undertaken to limit exposure. However, our data show 
that approximately 1% of US mesothelioma cases were diagnosed among men and women 
aged younger than 35 years (3% younger than 45 years). Because mesothelioma is rare in 
this age group, it has been suggested that these cases may have an increased genetic 
susceptibility to developing mesothelioma; however, several lines of evidence also point to 
asbestos as a contributing cause. First, some (but not all) case studies of mesothelioma 
among children and young adults have documented a history of asbestos exposure.42–45
Second, some studies have observed that people exposed to asbestos as children have 
increased risk of developing respiratory symptoms,46 radiographic abnormalities,47 and 
mesothelioma.48 Our study is in line with other studies that show a higher proportion of 
peritoneal mesotheliomas in this age group than in older age groups.42,45 The hypothesis 
that pleural and peritoneal mesothelioma share a common cause, notably exposure to 
asbestos, is supported by the high correlation we observed between pleural and peritoneal 
mesothelioma (r=0.7). This correlation is similar to those reported in cohorts of asbestos-
exposed workers49 and among the population of Italy.50 A study of the Lombardy Region 
Mesothelioma Registry found that patients with pleural and peritoneal mesothelioma had 
similar proportions of occupational (60%) and environmental/familial (7%) asbestos 
exposures.51 An ecological study of 33 countries found significant correlations between 
historical asbestos consumption and both pleural and peritoneal mesothelioma.27 Although 
asbestos is the overwhelming cause of mesothelioma, exposure to factors that also induce 
cell necrosis, inflammation, proliferation, or DNA damage, such as ionizing radiation, 
particularly in conjunction with asbestos exposure, may contribute to the development of 
mesothelioma.31,49 Genetic susceptibility may also play a role because only a fraction of 
people with history of asbestos exposure develop mesothelioma.52
Our data agree with studies that showed that female mesothelioma incidence tends to be 
higher in geographic regions with high rates of male mesothelioma incidence, suggesting a 
common exposure to asbestos.37,53 While men are primarily exposed to asbestos through 
occupation, women are exposed in other ways. Workers may have contaminated their homes 
with asbestos fibers carried on their clothes, shoes, and hair, thus, potentially exposing their 
families and other household members.54 Asbestos from mining and manufacturing 
industries can contaminate air and water near mining and manufacturing plants and along 
transportation routes to loading stations or warehouses.55,56 The correlation between male 
and female mesothelioma incidence and the regional variation in female mesothelioma 
incidence support the hypothesis that mesothelioma risk may be increased by ambient 
asbestos environmental pollution from industrial sources.55,57–59 Asbestos was banned from 
new uses in the United States by the US Environmental Protection Agency,60 but some US-
manufactured and imported products, such as roofing materials and brake linings, still 
contain asbestos.61 Worldwide, 2 million tons of asbestos were mined in 2011 (Russia, 
China, Kazakhstan, Canada, and Brazil accounted for 99% of production), and 200 million 
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tons are in reserve.11 One study has estimated that for every 170 tons of asbestos used, one 
person will die from mesothelioma.29
Current treatment options for mesothelioma are limited, particularly for peritoneal 
mesothelioma, but include a multimodal approach, including surgery, radiotherapy, and 
chemotherapy.6,62 Detecting and treating mesothelioma in its early manifestation may help 
increase the 5-year survival rate, which was only 8% in 2007.12 However, because clinical 
trials of early detection and treatment options have not yet yielded clinical benefits, 
preventing mesothelioma by controlling or eliminating asbestos exposure is indicated as the 
optimal approach.27,63
This study is subject to at least the following limitations. Because of migration, state-
specific mesothelioma rates may not reflect past asbestos exposure because mesothelioma 
may not have been diagnosed in the state where the asbestos exposure occurred, particularly 
given the long latency period between exposure and disease. Although the combined NPCR 
and SEER data provide 100% coverage of the United States, CIs are presented since our 
rates may be underestimates or estimates because of delays in case-reporting, misdiagnosis, 
or differential diagnosis. Delays in case-reporting can result in an underestimate for the most 
recent years. Although the possibility of misdiagnosis has diminished in recent years 
because current standards recommend that a malignant mesothelioma diagnosis be 
confirmed by biopsy and immunohistochemistry,4 some tumors, mainly carcinomas, may be 
misdiagnosed as mesothelioma, resulting in an overestimate.31 Conversely, some 
mesotheliomas, especially peritoneal mesotheliomas, may have been differentially 
diagnosed, particularly as serous papillary carcinomas of the peritoneum or ovary, resulting 
in an underestimate.31
This report shows that 3200 mesothelioma cases were diagnosed annually in the United 
States during 2003–2008; some of these cases occurred among young people who were born 
after the use of asbestos peaked. These data indicate that the US population is still at risk of 
exposure to asbestos, and possibly erionite, and developing mesothelioma. Even though 
advancements in early detection and treatment options offer promises of better prognosis of 
mesothelioma, these advancements have not yet resulted in improved survival for 
individuals who already have the disease. Therefore, prevention is a better option. 
Mesothelioma can be prevented by eliminating exposure to asbestos.27,63 Almost all 
products that use asbestos have a safer substitute,10,64 and NIOSH and OSHA standards can 
be followed to reduce occupational exposure to asbestos.34,35 Subsequent changes in 
mesothelioma incidence in the United States can be monitored by using national, 
population-based, cancer registry data.
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Figure 1. 
(A) Correlation between pleural mesothelioma incidence and peritoneal mesothelioma 
incidence within states, United States, 2003–2008 (Pearson correlation=0.70; P<0.0001). 
(B) Correlation between male mesothelioma incidence and female mesothelioma incidence 
within states, United States, 2003–2008 (Pearson correlation=0.78; P<0.0001). Correlation 
is shown as straight line and 95% confidence intervals are shown as shaded area. Analyses 
were weighted by the inverse variance of the male and female combined mesothelioma 
incidence rate and restricted to states where at least 16 cases were diagnosed for each sex or 
subsite to allow for reliable rates (i.e. 42 states for correlation by sex; 28 states for 
correlation by subsite). Data are from Centers for Disease Control and Prevention’s National 
Program of Cancer Registries and the National Cancer Institute’s Surveillance, 
Epidemiology, and End Results program that met US Cancer Statistics data quality criteria 
for each year during 2003–2008.
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Figure 2. 
Geographic distribution of malignant mesothelioma diagnosed in the United States, 2003–
2008. Map A depicts incidence rates (age-adjusted to the 2000 US standard population) with 
lighter colors indicating lower rates and darker colors indicating higher rates. Map B depicts 
average number of cases diagnosed each year 2003–2008 with lighter colors indicating 
lower numbers and darker colors indicating higher numbers. Data are from Centers for 
Disease Control and Prevention’s National Program of Cancer Registries and the National 
Cancer Institute’s Surveillance, Epidemiology, and End Results program that met US 
Cancer Statistics data quality criteria for each year during 2003–2008 (covering 100% of the 
US population).
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Figure 3. 
Malignant mesothelioma cases diagnosed in the United States by sex and year 2003–2008. 
The vertical scale on the left represents the number of malignant mesothelioma cases 
diagnosed annually. White bars represent cases among women, and gray bars represent 
cases among men. Numbers of cases are given within bars; the number of cases was stable 
over time (P<0.05). The vertical scale on the right represents the annual incidence rate of 
malignant mesothelioma per 100 000 persons, age-adjusted to the 2000 US standard 
population. Circles represent rates among women, and diamonds represent rates among men. 
Vertical lines around the data points represent 95% confidence intervals for the rate. Trend 
lines represent incidence trends estimated by using joinpoint regression. From 2003 to 2008, 
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malignant mesothelioma incidence rates declined by 2.6% per year among men (P<0.05) 
and were stable among women. Data are from the CDC’s National Program of Cancer 
Registries and the National Cancer Institute’s Surveillance, Epidemiology, and End Results 
program that met US cancer statistics data quality criteria for each year 2003–2008 
(covering 100% of the US population).
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